Recombinant vesicular stomatitis virus (VSV) is widely used as a vaccine platform. However, the capacity of VSV-based vaccines to induce mucosal immunity has not been fully investigated. In the present study, a recombinant VSV expressing coxsackievirus B3 (CVB3) major immunogen VP1 has been generated and the immune protection elicited by VSV-VP1 was evaluated. We demonstrated that intranasal delivery of VSV-VP1 can induce a potent antigen-specific mucosal immune response as well as a systemic immune response, particularly the induction of polyfunctional T cells. Importantly, mice immunized with VSV-VP1 were better protected against CVB3-induced viral myocarditis than those receiving a chitosan-formulated DNA vaccine. Increased dendritic cell (DC) maturation in the mesenteric lymph node (MLN) was observed in the mice vaccinated with VSV-VP1, which could be a potential mechanism for the protective immune response. These findings support VSV as a viral delivery vector that can induce robust mucosal immunity that should be considered for further vaccine development.
Introduction
Viral myocarditis (VMC) is induced by viral infection and often progresses to chronic myocarditis with persisting myocardial inflammation [1, 2] . Patients with severe cardiac dysfunction may also develop dilated cardiomyopathy [3] , which is one of the most frequent reasons for heart transplantation. Although many different infectious agents have been attributed as the cause of viral myocarditis, the enterovirus coxsackievirus B3 (CVB3) is considered to be the most common cause of heart disease in adults and children [4, 5] .
To date, many potential vaccines to prevent acute infection of myocarditis have been tested in animal models, including inactivated virus vaccines, attenuated virus vaccines, recombinant protein vaccines, DNA vaccines, and virus-like particle (VLP) vaccines [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Intramuscular immunization of mice with a DNA vaccine was reported to induce variable humoral and cellular immunities, resulting in the protection of mice against lethal CVB3 infection [6] [7] [8] . Although these studies are very promising, no effective clinical vaccine against CVB3 is currently available. Hence, there is still an urgent need to develop new vaccines to protect against CVB3 infection.
Previous studies have demonstrated the importance of both humoral and cellular immune responses for protection from CVB3. Agammaglobulinemic individuals are particularly susceptible to CVB3-associated encephalitis, and mice lacking B cells develop a chronic infection and remain viremic for at least 2 months; viremia can be alleviated by the adoptive transfer of B cells from CVB3immune wild-type mice [17] [18] [19] . Reports have also highlighted the importance of cellular immunity against CVB3-induced viral myocarditis. Comparison of C57BL/6 mice (resistant to chronic CVB3 myocarditis) and A.BY/SnJ mice (susceptible to chronic CVB3 myocarditis) found that a failure to clear the virus may be attributed to defects in dendritic cell (DC) maturation/activation and MHC class I antigen processing [20] . The neutralization of interleukin 17 (IL-17) increases both CD4 + and CD8 + T cells, which ameliorates the pathological cardiac changes and reduces viral replication [21] .
As a member of enteroviruses, CVB3 invades host through gastrointestinal tract [5] . Thus, it is important for a CVB3 vaccine to produce mucosal immunity at the sites of viral transmission to block the initial infection as well as the induction of potent systemic immune responses. A multitude of vehicles, including http://dx.doi.org/10.1016/j.vaccine.2014.05.052 0264-410X/© 2014 Elsevier Ltd. All rights reserved. microparticles, liposomes, and attenuated pathogens, have been developed as alternative platforms for mucosal delivery. Vesicular stomatitis virus (VSV), a viral vaccine vector, has been shown to be an excellent vector to deliver foreign antigens [22, 23] . Using reverse genetics, an exogenous gene can be inserted into the VSV genome and recombinant VSV can be recovered entirely from an infectious cDNA clone [24, 25] . The exogenous antigen is expressed continuously in vivo once the recombinant viruses are inoculated into animals, and thus it triggers specific immune responses. Recombinant VSV has been successfully developed for a number of vaccine candidates, such as human immunodeficiency virus [26] [27] [28] [29] , severe acute respiratory syndrome virus [30, 31] , hepatitis C virus [32, 33] , hepatitis B virus [34] , influenza virus [35] , papillomavirus [36] , human respiratory syncytial virus [37] , poxvirus [38] , Ebola virus, and Marburg virus [39, 40] . The VSV-based HIV vaccine candidate has been so successful in early studies that it has recently been moved to clinical study through the HIV Vaccine Design and Development Teams program [41] . Collectively, these studies have demonstrated the great potential of VSV-based vaccines to trigger strong immunity even after a single immunizing dose. In spite of this, the capacity of VSV-based vaccines to induce mucosal immunity has not yet been fully characterized.
We previously reported that a mucosal vaccine chito-pcDNA3.1-VP1, a DNA plasmid pcDNA3.1-VP1 encapsulated in a chitosan particle, protected mice against CVB3-induced viral myocarditis [14] . A moderate level of mucosal IgA and an IFN-␥ + T cell immune response were induced by intranasal immunization with chito-pcDNA3.1-VP1. To develop a more efficient vaccine, in the present study we have applied a VSV viral vector as a mucosal delivery system to express the main antigenic protein for CVB3 VP1. We evaluated the potential of this VSV-based vaccine to induce antigen-specific mucosal and systemic immunity in a viral myocarditis mouse model.
Materials and methods
The coding region of CVB3 (Nancy strain) major capsid protein VP1 was amplified by PCR from pcDNA3.1-VP1 [14] and cloned into the G-L junction of the pVSVXN 2 plasmid. Recombinant VSV containing VP1 (VSV-VP1) was recovered as previously described [22] . Six-week-old male BALB/c mice were purchased from the experimental animal center of Chinese Academy of Science (Shanghai, China) and remained in pathogen-free conditions and housed at the Soochow University School of Medicine animal facilities. All animal experiments were performed according to the guidelines for the Care and Use of Laboratory Animals (Ministry of Health, China, 1998) and the guidelines of the Laboratory Animal Ethical Commission of Soochow University. Mice were lightly anesthetized by injecting 0.75% pentobarbital sodium into cavum abdominis (30 mg/kg) prior to all immunizations. Each group contained 6 mice. For VSV-VP1 or VSV-GFP immunization, single dose of 10 6 plaqueforming units (PFU) viruses in a 25 l volume was intranasally administered. The group of mice receiving PBS alone was used as control. For chitosan-DNA immunization, each group of mice were mildly intranasally immunized with chitosan encapsulated 50 g pcDNA3.1-VP1 (chito-pcDNA3.1-VP1) or 50 g pcDNA3.1 (chito-pcDNA3.1) for 4 times biweekly. The detection of antibody response, lymphocyte proliferation assay, CTL activity assay, measurement of dendirtic cell maturation et al. as described previously [42] . All data are given as mean ± SD. Statistical analysis of the data was performed with the two-tailed independent Student's t-test using GraphPad Prism version 4.01 (GraphPad Software Incorporated). P < 0.05 was considered statistically significant. Full detailed methods are provided in Supplemental materials and methods.
Results

Construction and identification of the recombinant VSV based vaccines
The coding region of CVB3 main antigenic protein VP1 was amplified by PCR and cloned into pVSVXN2 plasmid at the G-L junction in the VSV genome by XhoI and NheI restriction enzymes as indicated in Fig. 1A . A VSV-GFP recombinant virus was generated as a control. We then recovered the recombinant viruses in BHK-21 cells as previously reported [24] and the recombinant viruses were purified by plaque assay. Immunofluorescence staining of VP1 indicated that VP1 was efficiently expressed in the cytoplasmic region of VSV-VP1-infected BHK-21 cells (Fig. 1B) . We also detected the expected green fluorescence in VSV-GFP infected cells. A western blot further confirmed the expression of VP1 as well as the expression of VSV glycoprotein VSVG in infected cells (Fig. 1C ). These results demonstrate the successful generation of recombinant virus VSV-VP1 expressing CVB3 antigen VP1.
The humoral response generated by VSV-VP1 vaccination
Administration of vaccines at mucosal surfaces has been shown to elicit an adequate local immune response at the administration site and at distant mucosal sites, as well as a systemic immune response [43] . Thus, groups of mice were intranasally immunized with VSV-VP1, VSV-GFP, chito-pcDNA3.1-VP1, chito-pcDNA3.1 and PBS described in Section 2. We monitored the weight change of immunized mice to assess the effects of viral infection. As previously reported [44] , mice inoculated with 10 6 PFU of either VSV-VP1 or VSV-GFP demonstrated severe weight loss as well as other clinical symptoms such as tremors, paralysis, and circling within the 6 days post inoculation but recovery was noted thereafter (data not shown). Meanwhile, the weight of mice immunized with chito-pcDNA3.1-VP1, chito-pcDNA3.1 and PBS steadily increased, and were not significantly different from those of VSV-VP1 and VSV-GFP groups 2 weeks post inoculation.
To analyze the antibody response in the immunized mice, blood samples were collected from each mouse and the serum IgG antibody response was determined by ELISA at indicated time points. As shown in Fig. 2A mice immunized with a single dose of VSV-VP1 exhibited a high serum IgG response compared with that of mice immunized with VSV-GFP and it peaked at week 4 post inoculation with a drop in the following weeks. The serum IgG level in mice receiving chito-pcDNA3.1-VP1 gradually increased with three additional boosts and reached a peak at week 8. Interestingly, although the trend of fecal secretory IgA (sIgA) generated by VSV-VP1 was similar to that for serum IgG, its production was faster and higher than that in chito-pcDNA3.1-VP1 immunized mice (Fig. 2B) . These results indicate that intranasal immunization with VSV-VP1 can efficiently induce both mucosal and systemic antibody responses.
Vaccination of mice with VSV-VP1 elicits strong cellular immunity
We next investigated the CVB3-specific T cell immune responses in the spleen and mesenteric lymph node (MLN) induced by VSV-VP1 immunization. As shown in Fig. 3A , compared with mice given PBS or VSV-GFP, mice immunized with VSV-VP1 displayed a significant increase in specific T cell proliferation in both the spleen and MLN as measured by BrdU assay (P < 0.001). This proliferation level was even higher than that of mice immunized with chito-pcDNA3.1-VP1 (P < 0.05).
An IFN-␥ ELISPOT analysis indicated that mice immunized with VSV-VP1 developed the most IFN-␥-secreting T cells in the spleen and MLN, with frequencies reaching 351 and 255 spot-forming cells (SFC)/10 6 cells, respectively ( Fig. 3B ; P < 0.05). Mice immunized with chito-pcDNA3.1-VP1 produced a modest amount of IFN-␥ secreting T cells compared with control groups. In agreement with the ELISPOT data, the strongest CVB3-specific cytotoxicity responses were also detected in the splenic (50.3%) and mesenteric lymphocytes (51.1%) derived from mice immunized with VSV-VP1 at an E:T ratio of 50:1 (Fig. 3C ). Taken together, these data indicate that in addition to the previously reported VSV-induced specific systemic T cell immune responses against other viral pathogens, VSV-based vaccines can also induce a strong mucosal antigenspecific T cell immune response.
VSV-VP1 vaccination significantly alleviates CVB3-induced viral myocarditis
To determine if VSV-VP1 immunization has protective effects, 2 weeks after the final DNA vaccine immunization, all of groups mice were infected with a 50% lethal dose (LD 50 ) of 3 of CVB3 to induce acute myocarditis. Seven days post-viral infection, mice in the groups vaccinated with PBS, VSV-GFP or chito-pcDNA3.1 suffered from loss of body weight, up to approximately 17.9% of total weight (Fig. 4A) , indicating the development of myocarditis in these mice. Detection of serum creatine kinase (CK) and CK-MB activity reflects the amount of cardiac damage. Immunization with VSV-VP1 significantly reduced the serum CK and CK-MB activity ( Fig. 4B and C) . For example, CK-MB in the VSV-VP1 immunized group was only 631.3 IU/L, while it was 1420.0 IU/L in the VSV-GFP immunized group. Additionally, the viral titer of heart tissue in the VSV-VP1 immunized group was at least 250-fold lower than that of the VSV-GFP immunized group (Fig. 4D ). Histology analysis of hematoxylin and eosin (HE)-stained heart sections showed a large amount of myocyte necrosis and immune-infiltration in the control (PBS), VSV-GFP and chito-pcDNA3.1 immunized groups. Only a tiny amount of inflammation was seen in the VSV-VP1 immunized group, suggesting that this vaccination prevented the development of myocarditis (Fig. 4E ). Similar results were also observed in HEstained pancreas sections (Fig. S2) .
In vivo ventricular systolic function was measured by fractional shortening (FS) and ejection fraction (EF) using an echocardiography assay (Fig. 5A) . The left ventricular FS (LVFS) in chito-pcDNA3.1-VP1 immunized mice was ∼12% lower compared with that in the VSV-VP1 immunized group. When left ventricular EF (LVEF) was calculated, it was ∼10% lower in chito-pcDNA3.1-VP1 immunized mice compared with that in the VSV-VP1 immunized group (Fig. 5B) , indicating that in vivo ventricular function after infection was improved by prior immunization with VSV-VP1.
To further evaluate the protective abilities of the vaccine candidates, mice were challenged with 5 LD 50 of CVB3 2 weeks after the final DNA immunization. All mock-immunized mice succumbed to severe illness and died within 8 days, while 41.67% (5/12) of the chito-pcDNA3.1-VP1 immunized mice and 66.67% (8/12) of the VSV-VP1 immunized mice survived to 14 days with no signs of illness (Fig. 5C ), indicating that nasal immunization with VSV-VP1 provides some protection against CVB3-induced myocarditis. 
VSV-VP1 immunization promotes dendritic cell (DC) maturation and increases frequency of polyfunctional T cells
As DC play an important role in the induction of the adaptive immune response, we further examined the maturation of MLN DC in the immunized mice using flow cytometry. Two weeks after final immunization, MLN cells were isolated and stained by maturation makers MHCII, CD40, CD80 or CD86 together with CD11c, which is a characteristic marker of myeloid-derived DC. Few DC fully maturated in the VSV-GFP, chito-pCDNA3.1 and PBS immunized groups. Intranasal immunization with chito-pcDNA3.1-VP1 mildly promoted DC maturation compared with the levels of maturation seen for the VSV-VP1 immunized group, in which the cell surface expressions of MHCII, CD40, CD80 or CD86 molecules were efficiently up-regulated ( Fig. 6A ; P < 0.05).
To further explore the consequences of DC maturation, we next measured the development of polyfunctional T cells. Previous reports have shown that T cells with multiple effector functions, such as the concomitant production of IFN-␥, TNF-␣, and IL-2, are functionally superior to their single cytokine-producing counterparts for the clearance of viral pathogens [45, 46] . Therefore, we evaluated the phenotype and proportion of polyfunctional T cells in immunized mice using intracellular cytokine staining.
Multiple T cell populations could be delineated based on the expression of IFN-␥, IL-2 and TNF-␣. CD4 + or CD8 + T population was first gated, and the expression levels of IFN-␥, TNF-␣, and IL-2 were further analyzed. Single-positive CD4 + or CD8 + T cells expressing IFN-␥, TNF-␣, or IL-2 was significantly increased in the VSV-VP1 immunization group (4.64% for CD4 + IFN-␥ + , 16.48% for CD4 + IL-2 + and 23.04% for CD4 + TNF-␣ + ) upon VP1 peptide stimulation and was significantly higher than those in the chito-pcDNA3.1-VP1 immunization group. T cells expressing these cytokines were barely detectable in the control immunization groups: VSV-GFP, chito-pcDNA3.1 and PBS ( Fig. 6B ; P < 0.05). To assess whether VSV-VP1-induced T cells were producing more than one of these cytokines, we next examined the co-expression patterns of IFN-␥, TNF-␣, and IL-2. Analysis of IFN-␥ + TNF-␣ + , IFN-␥ + IL-2 + , and TNF-␣ + IL-2 + double-positive CD4 + T cells revealed that the proportion of IFN-␥ + IL-2 + cells was the lowest (1.69% for the VSV-VP1 immunized group and 0.88% for the chito-pcDNA3.1-VP1immunized group). TNF-␣ + IL-2 + double-positive T cells were the most abundant, reaching 18.10% for the VSV-VP1 immunized group and 7.92% for the chito-pcDNA3.1-VP1 immunized group. The percentage of the IFN-␥ + TNF-␣ + IL-2 + triple-positive polyfunctional cells was higher than that of the IFN-␥ + TNF-␣ + double-positive cells (4.28% for the VSV-VP1 immunized group and 1.52% for the chito-pcDNA3.1-VP1 immunized group). Similar levels of IFN-␥, TNF-␣, and IL-2 expression were seen in CD8 + T cells (Fig. 6C) . Analysis of the proportions of the single-, double-, or triple-positive T cells in the VSV-VP1 and chito-pcDNA3.1-VP1 immunization groups indicated that VSV-VP1 immunization can enhance the magnitude of polyfunctional CD4 + and CD8 + T cells as detected by increased double-, or triple-positive populations (Fig. 6D ).
Discussion
In the present study, we generated a VSV-based vaccine encoding CVB3 major antigenic protein VP1. Although VSV-based vectors have been widely used as vaccine platforms, few studies have characterized the capacity of VSV-based vaccines to induce potent mucosal immunity. We compared the antigen-specific mucosal immunity elicited by intranasal administration of a VSV-VP1 vaccine with that of a chitosan-based mucosal vaccine, chitosan-pcDNA3.1-VP1 [14] . With a single-dose intranasal delivery of VSV-VP1, mice exhibited significantly higher levels of both mucosal and systemic immune responses than mice vaccinated with chito-pcDNA3.1-VP1. This improvement in multiple aspects of immunity is one of the most important virtues of mucosal vaccination [43] . While the peak levels of antigen-specific fecal sIgA in the VSV-VP1 and chito-pcDNA3.1-VP1 groups were similar, the induction of antigen-specific sIgA in the VSV-VP1 immunized group was much faster than that in the chito-pcDNA3.1-VP1 immunized group. Since the same antigen, VP1, was used for both delivery systems in this study, these results demonstrate that the VSV-based vector is more potent at inducing mucosal immunity than the chitosan-based delivery system. The increased protection against viral myocarditis in VSV-VP1 immunized mice may result from the elevated humoral response as well as the cellular immunity comparing to that of chito-pcDNA3.1-VP1.
Oral delivery is a simple alternate way to induce mucosal immunity. Ma et al. found that a VSV-based vaccine against human norovirus administrated with the combination of intranasal and oral delivery could induce antigen-specific IgA in both the gastrointestinal tract and vagina [47] . Based on their success with oral delivery, it would likely be worthwhile to investigate the capacity of VSV-VP1 vaccination to induce mucosal and systemic immunity by oral delivery, alone or in combination with intranasal delivery.
Several features make VSV an ideal CVB3 vaccine delivery mechanism. First, VSV can induce strong mucosal immunity by intranasal or oral immunization. Because the gastrointestinal tract is the main route through which CVB3 invades the host, it is critical to induce mucosal immune responses that can block virus infection at the initial stage and the primary site. Second, being a virus, VSV can induce strong cellular immunity to compensate the impaired cellular immunity after CVB3 infection. Kemball et al. found that CVB3 infection rapidly induces phenotypic changes in conventional DC, and markedly impairs specific CD8 + T cell antigen presentation through MHCI pathway in vivo [48, 49] . Third, the VSV reverse genetics system is well characterized and easy to manipulate [24, 25] . High titers of recombinant VSV can be achieved by propagating virus in mammalian cell lines approved for vaccine production. Compared with other potential vaccine platforms such as baculovirus, the VSV system is faster and less expensive. Finally, VSV vaccines can be administered needle-free. This is especially valuable for people who live in rural regions that are short of health care.
The polyfunctional T cells induced by immunization with VSV-VP1 are an important component of the robust immune response induced by this vaccine. Numerous studies have shown that the quality, rather than the level, of T cell responses is crucial for determining the outcome of various infections [45, 46, 50] . For HCV, it was reported that the resolution obtained under early interferon therapy correlated with the development of polyfunctional IFN-␥/IL-2/CD107␣ + specific CD8 + T cells [51] . While the chito-pcDNA3.1-VP1 vaccine could induce some polyfunctional T cells (1.52% triple-positive IFN-␥ + TNF-␣ + IL-2 + CD4 + T cells), immunization with VSV-VP1 resulted in the striking increase of this population up to 4.28%. In addition, the VSV-VP1 vaccine induced up to 18.10% double-positive TNF-␣ + IL-2 + CD4 + T cells. Based on previous studies, we speculate that these polyfunctional T cells could establish long-lasting immunological memory and will likely give rise to a strong and robust secondary response upon challenge with CVB3.
DC play a central role in priming immune responses and are therefore of interest for vaccine capacity. The immunological paradigm holds that DC capture antigens, while inflammatory signals trigger their maturation and migration to the draining lymph nodes to initiate an antigen-specific immune response. Viral vectors, such as recombinant adenovirus 35, that can efficiently infect and cause maturation of DC in vivo induce optimal vaccine responses [52] . As previously described in vitro for BMDC [53, 54] , we observed that VSV infection significantly improved the maturation of MLN DC through the up-regulation of different molecules 2 weeks post-final immunization. One reason for this might be that the stimulation caused by VSV infection is stronger and lasts longer than that caused by chitosan-incorporated DNA at the sites of immunization. The increased maturation of MLN DC in VSV-VP1immunized mice likely results from the sustained migration and activation of peripheral DC from the inoculation site. Additional experiments are ongoing to address this hypothesis.
This study characterized the potency of a VSV-based vaccine vector for the induction of mucosal immunity. Vaccination with VSV-VP1 promoted mucosal DC maturation, enhanced antigenspecific mucosal immunity as well as systemic immunity, and could alleviate CVB3-induced viral myocarditis. Our study might also provide insight into the importance of mucosal immunity for the further development of VSV-based vaccines.
